Illumina (NASDAQ: ILMN) today announced a series of product and
technology innovations for its powerful sequencing ecosystem - from
sample preparation to system enhancements to data analysis -- that will
enable the next breakthroughs in understanding the genome.
"Illumina has consistently led the market in conceptualizing,
developing, and executing on industry-changing sequencing technology,
and we continue to provide scientific advances that facilitate fully
integrated and highly economical sequencing with very rapid turnaround,"
said Jay Flatley, President and Chief Executive Officer of Illumina.
"These capabilities allow us to continue to meet the evolving needs of
our customers, as they develop an ever-increasing range of applications,
in new and emerging markets from agrigenomics to molecular diagnostics."
Sample Prep Evolution
Simplifying and accelerating the sample prep process is fundamental to
improving sequencing workflows and decreasing turnaround time, an
important factor for sequencing to be adopted in clinical settings.
Illumina announced and previewed several innovations in sample
Illumina also highlighted a number of core sequencing platform
enhancements that will increase the throughput, read lengths, and speed
of existing systems, as well as decrease running costs.
Illumina also shared today a development in the evolution of its
cloud-based data analysis, storage, and sharing platform, BaseSpace™ (www.illumina.com/basespace):
"Our ability to rapidly innovate across the entire workflow of
next-generation sequencing ensures we are better positioned than ever to
continue creating and delivering value to both our research and clinical
customers," said Christian Henry, Senior Vice President and General
Manager of Illumina's Genomic Solutions business. "With enhancements to
our platform, we continue to set the standard for speed, accuracy,
output, and workflow."
is a leading developer, manufacturer, and marketer of life science tools
and integrated systems for the analysis of genetic variation and
function. We provide innovative sequencing and array-based solutions for
genotyping, copy number variation analysis, methylation studies, gene
expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products
accelerate genetic analysis research and its application, paving the way
for molecular medicine and ultimately transforming healthcare.
This release contains forward looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are
not limited to, statements we make regarding the expected shipping and
availability dates for new sample preparation products and technology
enhancements. Important factors that could cause actual results to
differ materially from those in any forward-looking statements include
challenges inherent in developing, manufacturing, and launching new
products and services and the other factors that are detailed in our
filings with the Securities and Exchange Commission, including our most
recent filings on Forms 10-K and 10-Q, or in information disclosed in
public conference calls, the date and time of which are released
beforehand. We do not intend to update any forward-looking statements
after the date of this release.
[ Back To NFVZone's Homepage ]